tiprankstipranks
TipRanksStock Market NewsBLU NewsH.C. Wainwright Keeps Their Buy Rating on BELLUS Health (BLU)
Blurbs

H.C. Wainwright Keeps Their Buy Rating on BELLUS Health (BLU)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on BELLUS Health (BLUResearch Report), with a price target of $14.00. The company’s shares closed last Monday at $5.66.

According to TipRanks.com, Fein has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -2.8% and a 34.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Global Blood Therapeutics, and Deciphera Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for BELLUS Health with a $16.50 average price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $9.84 and a one-year low of $2.60. Currently, BELLUS Health has an average volume of 3.11M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BELLUS Health, Inc. is a biopharmaceutical development company which engages in the research and development of novel therapeutics for the treatment of chronic cough and other hypersensitisation disorders. Its product, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

Read More on BLU:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More